These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11929710)

  • 1. Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC).
    Nakano T; Inoue K; Hirohara J; Arita S; Higuchi K; Omata M; Toda G
    Hepatol Res; 2002 Apr; 22(4):250-260. PubMed ID: 11929710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
    van Hoogstraten HJ; Hansen BE; van Buuren HR; ten Kate FJ; van Berge-Henegouwen GP; Schalm SW
    J Hepatol; 1999 Aug; 31(2):256-62. PubMed ID: 10453938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile of primary biliary cirrhosis that was diagnosed as symptomatic primary biliary cirrhosis according to the revised diagnostic criteria in Japan.
    Azemoto N; Abe M; Murata Y; Murakami H; Matsuura B; Hiasa Y; Onji M
    Intern Med; 2010; 49(12):1073-8. PubMed ID: 20558920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical course and prognosis of primary biliary cirrhosis--multivariant analysis on cases of national survey].
    Inoue K; Sasaki H; Yasuyama T; Higuchi K; Naruse M; Matsubara I; Oka H; Toda G
    Nihon Shokakibyo Gakkai Zasshi; 1989 Apr; 86(4):889-96. PubMed ID: 2754840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
    Corpechot C; Chazouillères O; Poupon R
    J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?
    Kilmurry MR; Heathcote EJ; Cauch-Dudek K; O'Rourke K; Bailey RJ; Blendis LM; Ghent CN; Minuk GY; Pappas SC; Scully LJ; Steinbrecher UP; Sutherland LR; Williams CN; Worobetz LJ
    Hepatology; 1996 May; 23(5):1148-53. PubMed ID: 8621147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
    Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical features and prognosis of primary biliary cirrhosis in Korea].
    Kim KA; Jeong SH; Lee JI; Yeon JE; Lee HJ; Kwon SY; Chang UI; Min HJ
    Korean J Hepatol; 2010 Jun; 16(2):139-46. PubMed ID: 20606498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
    Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural history of PBC: has it changed?
    Lee YM; Kaplan MM
    Semin Liver Dis; 2005 Aug; 25(3):321-6. PubMed ID: 16143947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathological features of early- and late-stage primary biliary cirrhosis: a comparative study].
    Zhao SX; Zhang YG; Zhou GD; Wang RQ; Zhang QS; Li WC; Ren WG; Nan YM; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):412-6. PubMed ID: 27465943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
    Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H;
    Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
    ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
    Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan.
    Harada K; Hirohara J; Ueno Y; Nakano T; Kakuda Y; Tsubouchi H; Ichida T; Nakanuma Y
    Hepatology; 2013 May; 57(5):1942-9. PubMed ID: 23197466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.
    Almasio PL; Floreani A; Chiaramonte M; Provenzano G; Battezzati P; Crosignani A; Podda M; Todros L; Rosina F; Saccoccio G; Manenti F; Ballardini G; Bianchi FP; Scheuer PJ; Davies SE; Craxì A
    Aliment Pharmacol Ther; 2000 Dec; 14(12):1645-52. PubMed ID: 11121914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.